A Phase II Trial of R435(Bevacizumab) in stage IVB, persistent or recurrent carcinoma of the cervix

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222700

Enrollment

Registered

2014-12-19

Start date

2014-12-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced or recurrent carcinoma of the cervix

Interventions

investigational material(s) Generic name etc : Bevacizumab INN of investigational material : Bevacizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigat

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: - Adult patients, >=20 years of age. - GOG Performance Status of 0 or 1. - Primary stage IVB, persistent or recurrent carcinoma of the cervix which is not amenable to curative treatment.

Exclusion criteria

Exclusion criteria: - Previously treated with chemotherapy except when used concurrently with radiation therapy. - Serious non-healing wound, ulcer, or bone fracture. This includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months must pass before study entry. - History or evidence upon physical examination of CNS disease. - History of hemoptysis(>=Grade2) within 1 month before study entry.

Design outcomes

Primary

Measure	Time frame
Tolerability CTCAE ver4.03	—

Secondary

Measure	Time frame
Safety, Efficacy CTCAE ver4.03, RECIST ver1.1	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026